JP7515480B2 - 認知障害の治療に使用するための3β-(ベンジルオキシ)-17α-メチル-プレグン-5-エン-20-オン - Google Patents
認知障害の治療に使用するための3β-(ベンジルオキシ)-17α-メチル-プレグン-5-エン-20-オン Download PDFInfo
- Publication number
- JP7515480B2 JP7515480B2 JP2021534632A JP2021534632A JP7515480B2 JP 7515480 B2 JP7515480 B2 JP 7515480B2 JP 2021534632 A JP2021534632 A JP 2021534632A JP 2021534632 A JP2021534632 A JP 2021534632A JP 7515480 B2 JP7515480 B2 JP 7515480B2
- Authority
- JP
- Japan
- Prior art keywords
- 3bn17mep
- cognitive
- mice
- syndrome
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306716.4 | 2018-12-18 | ||
| EP18306716.4A EP3669876A1 (en) | 2018-12-18 | 2018-12-18 | 3béta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders |
| PCT/EP2019/085927 WO2020127468A1 (en) | 2018-12-18 | 2019-12-18 | 3β-(BENZYLOXY)-17α-METHYL-PREGN-5-EN-20-ONE FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022515373A JP2022515373A (ja) | 2022-02-18 |
| JP2022515373A5 JP2022515373A5 (cg-RX-API-DMAC7.html) | 2022-12-26 |
| JP7515480B2 true JP7515480B2 (ja) | 2024-07-12 |
Family
ID=65278139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021534632A Active JP7515480B2 (ja) | 2018-12-18 | 2019-12-18 | 認知障害の治療に使用するための3β-(ベンジルオキシ)-17α-メチル-プレグン-5-エン-20-オン |
Country Status (26)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021007382A (es) | 2018-12-18 | 2021-07-15 | Merck Sharp & Dohme Llc | Derivados de pirimidona como agentes citotoxicos selectivos contra celulas infectadas por vih. |
| WO2024085245A1 (ja) | 2022-10-21 | 2024-04-25 | 国立大学法人高知大学 | 術後せん妄の抑制薬 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006525298A (ja) | 2003-05-01 | 2006-11-09 | ヴァーナリス リサーチ リミテッド | アゼチジンカルボキサミド誘導体及びcb1レセプター媒介障害の治療におけるその使用 |
| JP2010531874A (ja) | 2007-06-28 | 2010-09-30 | インターベット インターナショナル ベー. フェー. | Cb1アンタゴニストとしての置換ピペラジン |
| JP2014515361A (ja) | 2011-05-20 | 2014-06-30 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Cb1受容体のアンタゴニスト |
| JP2016501871A (ja) | 2012-11-28 | 2016-01-21 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | プレグネノロンの3−(4’−置換)−ベンジル−エーテル誘導体 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE496894T1 (de) | 2006-07-14 | 2011-02-15 | Pfizer Prod Inc | Tartratsalz von (7s)-7-ä(5-fluor-2- |
| LT2976074T (lt) * | 2013-03-19 | 2020-03-25 | Universitat Pompeu-Fabra | Kanabinoido receptoriaus cb1 antagonistai, skirti naudoti gydant ligas, susijusias su neuronų dendritų anomalijomis |
| IL276697B2 (en) | 2018-02-20 | 2024-08-01 | Aelis Farma | 3beta-(4-methoxybenzyloxy)paragan-5-en-20-one for use in the treatment of cannabinoid-related disorders |
-
2018
- 2018-12-18 EP EP18306716.4A patent/EP3669876A1/en not_active Withdrawn
-
2019
- 2019-12-18 BR BR112021011654-0A patent/BR112021011654A2/pt unknown
- 2019-12-18 MD MDE20211041T patent/MD3897655T2/ro unknown
- 2019-12-18 FI FIEP19831675.4T patent/FI3897655T3/fi active
- 2019-12-18 HU HUE19831675A patent/HUE068626T2/hu unknown
- 2019-12-18 WO PCT/EP2019/085927 patent/WO2020127468A1/en not_active Ceased
- 2019-12-18 SI SI201930837T patent/SI3897655T1/sl unknown
- 2019-12-18 LT LTEPPCT/EP2019/085927T patent/LT3897655T/lt unknown
- 2019-12-18 KR KR1020217019491A patent/KR102845328B1/ko active Active
- 2019-12-18 CN CN201980081303.1A patent/CN113260366B/zh active Active
- 2019-12-18 JP JP2021534632A patent/JP7515480B2/ja active Active
- 2019-12-18 PL PL19831675.4T patent/PL3897655T3/pl unknown
- 2019-12-18 DK DK19831675.4T patent/DK3897655T3/da active
- 2019-12-18 ES ES19831675T patent/ES2987823T3/es active Active
- 2019-12-18 MX MX2021006904A patent/MX2021006904A/es unknown
- 2019-12-18 EP EP19831675.4A patent/EP3897655B1/en active Active
- 2019-12-18 CA CA3118210A patent/CA3118210C/en active Active
- 2019-12-18 RS RS20241106A patent/RS66013B1/sr unknown
- 2019-12-18 AU AU2019409912A patent/AU2019409912B2/en active Active
- 2019-12-18 SM SM20240425T patent/SMT202400425T1/it unknown
- 2019-12-18 MA MA54518A patent/MA54518B1/fr unknown
- 2019-12-18 US US17/414,826 patent/US12583884B2/en active Active
- 2019-12-18 PT PT198316754T patent/PT3897655T/pt unknown
- 2019-12-18 IL IL284032A patent/IL284032B2/en unknown
- 2019-12-18 HR HRP20241376TT patent/HRP20241376T1/hr unknown
-
2021
- 2021-05-14 ZA ZA2021/03284A patent/ZA202103284B/en unknown
- 2021-06-03 CL CL2021001458A patent/CL2021001458A1/es unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006525298A (ja) | 2003-05-01 | 2006-11-09 | ヴァーナリス リサーチ リミテッド | アゼチジンカルボキサミド誘導体及びcb1レセプター媒介障害の治療におけるその使用 |
| JP2010531874A (ja) | 2007-06-28 | 2010-09-30 | インターベット インターナショナル ベー. フェー. | Cb1アンタゴニストとしての置換ピペラジン |
| JP2014515361A (ja) | 2011-05-20 | 2014-06-30 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Cb1受容体のアンタゴニスト |
| JP2016501871A (ja) | 2012-11-28 | 2016-01-21 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | プレグネノロンの3−(4’−置換)−ベンジル−エーテル誘導体 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11517572B2 (en) | Killing senescent cells and treating senescence-associated conditions using a SRC inhibitor and a flavonoid | |
| US20220202798A1 (en) | Use of pridopidine for the treatment of fragile x syndrome | |
| JP2020530847A (ja) | プリドピジンによる筋萎縮性側索硬化症の治療方法 | |
| JP2009102343A (ja) | ダウン症候群を有する成人において認知低下を阻害する方法 | |
| NO327233B1 (no) | Anvendelse av en glukokortikoidreseptorantagonist for fremstilling av et medikament til forbedring av psykose hos en pasient. | |
| CN105744932A (zh) | 用于治疗神经障碍的包含托拉塞米和巴氯芬的组合物 | |
| AU2019409912B2 (en) | 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders | |
| JP2003527342A (ja) | 軽度認知障害を処置する方法 | |
| US20200345746A1 (en) | Oxazine Derivative for Use in the Prevention of Alzheimer's Disease in at Risk Patents | |
| RU2796005C2 (ru) | 3β-(БЕНЗИЛОКСИ)-17α-МЕТИЛ-ПРЕГН-5-ЕН-20-ОН ДЛЯ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ КОГНИТИВНЫХ РАССТРОЙСТВ | |
| HK40060558B (en) | 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders | |
| HK40060558A (en) | 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders | |
| EP3755339B1 (en) | 3-beta-(4-methoxybenzyloxy)pregn-5-en-20-one for use in the treatment of cannabinoids-related disorders | |
| HK40016661A (en) | Pridopidine for use in the treatment of fragile x syndrome | |
| HK40016661B (en) | Pridopidine for use in the treatment of fragile x syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221212 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221212 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231130 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231205 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240304 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20240304 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240611 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240702 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7515480 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |